Iopofosine-131, an experimental cancer-targeting agent, has recently been granted the FDA’s breakthrough therapy designation for the treatment of relapsed or refractory Waldenstrom macroglobulinemia (r/r WM). Highlighting its potential to substantially improve clinical outcomes over existing treatments, this designation underlines the drug’s promising therapeutic potential in this challenging clinical setting. The breakthrough therapy status was conferred […]
